Sepsis-associated thrombocytopenia
Conditions
Interventions
Hetrombopag combined with recombinant human thrombopoietin rhTPO treatment:None
Basic treatment group (using routine symptomatic supportive care):None
single-drug treatment group (treated only with rhTPO):None
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. It meets the diagnostic criteria for sepsis and SAT, and thrombocytopenia occurs during the course of sepsis; 3. Receive rhTPO monotherapy or heltrombopag combined with rhTPO, with a clear treatment plan, traceable dosage and course of treatment; 4. The clinical data are complete, including general demographic characteristics, underlying diseases, causes of sepsis, laboratory tests, treatment plans, therapeutic effects and adverse reactions, clinical outcomes, etc.; 5. No other platelet-stimulating drug therapy was received before treatment, and platelet transfusion was not performed (or the platelet transfusion time was after platelet-stimulating therapy, which did not affect the efficacy evaluation).
Exclusion criteria
Exclusion criteria: 1. Hematological malignancies; 2. Thrombocytopenia related to radiotherapy and chemotherapy; 3. Spleen hyperactivity due to liver cirrhosis; 4. Heparin-induced thrombocytopenia; 5. Active massive hemorrhage; 6. Pregnancy/Lactation; 7. ICU stay < 24 hours.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet count on day 14, platelet recovery on days 7 and 10,; 28-day mortality; ICU length of stay; incidence of bleeding events;improvement in clinical outcomes; | — |
Countries
China
Contacts
Public ContactCantang Zhang
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed